← All trials
NCT05130567
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 15, 2021
- Primary completion
- Jun 15, 2022
- Completion date
- Jul 30, 2022
- First posted
- Nov 23, 2021
- Last posted
- Nov 23, 2021
- Enrollment
- 88
- Arms / groups
- 6 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Guangzhou Lupeng Pharmaceutical Company LTD.Lead sponsor
- Nanfang Medical UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.